Monoclonal Antibody to Glutamate Receptor, Ionotropic, N-Methyl-D-Aspartate 2D (GRIN2D)
| Code | Size | Price |
|---|
| MAE809Hu22-20ul | 20ul | £92.00 |
Quantity:
| MAE809Hu22-100ul | 100ul | £173.00 |
Quantity:
| MAE809Hu22-200ul | 200ul | £235.00 |
Quantity:
| MAE809Hu22-1ml | 1ml | £542.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
EB11; NMDAR2D; NR2D; N-Methyl-d-Aspartate Receptor Subunit 2D; Glutamate [NMDA] receptor subunit epsilon-4
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
Ig Isotype:
IgG1 Kappa
Immunogen:
RPE809Hu01-Recombinant Glutamate Receptor, Ionotropic, N-Methyl-D-Aspartate 2D (GRIN2D)
Item Name:
Glutamate Receptor, Ionotropic, N-Methyl-D-Aspartate 2D
Potency (Clone Number):
D5
Source:
Monoclonal antibody preparation
Subcategory:
Monoclonal antibody preparation
USAGE:
Western blotting: 0.5-2ug/mL;<br/>Immunohistochemistry: 5-20ug/mL;<br/>Immunocytochemistry: 5-20ug/mL;<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Glutamate Receptor, Ionotropic, N-Methyl-D-Aspartate 2D (GRIN2D) | RPE809Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||